Loading…
2 companies · GEL, thousands · columns ordered by revenue
| Line item | Lab Express | Molekuluri Diagnostikis… |
|---|---|---|
| Total Revenue | 1,837 | 1,031 |
| Total COGS | -1,322 | -227 |
| Gross Profit | 515 | 805 |
| Gross Margin | 28.0% | 78.0% |
| Total Operating Expenses | -260 | -934 |
| EBITDA | 255 | -129 |
| EBITDA Margin | 13.9% | -12.6% |
| Total D&A | -27 | -119 |
| EBIT / Operating Income | 229 | -248 |
| Total Other Income | 3 | -0 |
| Profit Before Tax | 231 | -248 |
| Total Income Tax | -61 | 0 |
| Net Profit / (Loss) | 170 | -130 |
| Net Margin | 9.2% | -12.6% |
| Total Interest Income | — | 0 |
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Lab Express | (unclassified) | 13.9% | 58th pct | 1208 |
| Molekuluri Diagnostikis… | Healthcare Services | -12.6% | 12th pct | 268 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.